FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

Vashington,	Γ	20E40	
vasiliigion,	D.C.	20349	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL			
OMB Number: 3235-0287			
Estimated average burden			
hours per response	: 0.5		

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person (Check all applicable) Verrica Pharmaceuticals Inc. [VRCA] **Ballaron** Craig Director 3. Date of Earliest Transaction (Month/Day/Year) Officer (give title Other (specify 06/08/2023 below) below) (Last) (Middle) (First) C/O VERRICA PHARMACEUTICALS INC. 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) 44 WEST GAY STREET, SUITE 400 X Form filed by One Reporting Person Form filed by More than One Reporting (Street) Person WEST 19380 PA **CHESTER** Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to (City) (State) (Zip) satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature 1. Title of Security (Instr. 3) Transaction of Indirect Execution Date, Securities Beneficially Form: Direct (Month/Day/Year if any (Month/Day/Year) Code (Instr. (D) or Indirect Beneficial Owned Following 8) (I) (Instr. 4) Ownership (Instr. 4) Reported Transaction(s) (A) or Code Amount Price (Instr. 3 and 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative 6. Date Exercisable and 3. Transaction 3A. Deemed Execution Date 5. Number 9. Number of 11. Nature 7. Title and 8. Price of Derivative Conversion Transaction Expiration Date Amount of derivative Ownership of Indirect if any (Month/Day/Year) Security (Instr. 3) or Exercise (Month/Day/Year Code (Instr. 8) Derivative (Month/Day/Year) Securities Security (Instr. 5) Securities Beneficially Form: Direct (D) Beneficial Price of Securities Underlying Derivative Security Ownership Derivative Acquired or Indirect (Instr. 4) (A) or Disposed (Instr. 3 and 4) Following (I) (Instr. 4) Security Reported of (D) (Instr. 3, 4 and 5) Transaction(s) (Instr. 4) Amount Number Date Exercisable Expiration Date Code (A) (D) Title Shares Stock Option \$5.7 06/08/2023 10,384 (1) 06/07/2033 10,384 \$0.00 10,384 D (right to Stock

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in 12 equal monthly installments beginning on July 8, 2023 and, in any event, will be fully vested on the date of the next annual meeting of stockholders, subject to continued service as a director though the applicable vesting date

Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact ** Signature of Reporting Person

06/12/2023

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.